pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

Skylark Bio SKY-GJB2 Gene Therapy

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Unknown

Primary summary from verified readiness

Confidence
69% · fresh
Computed at
2026-08-20T10:56:06.020457+00:00
Claimed
20

Public ambition and stated capability

Reported
16

Observed practitioner reporting

Verified
10

Independently supported evidence

Gap
+10

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Track; not yet

Why
Genuine, tier-2-corroborated first-in-human milestone (real dosing event, real mechanism, real trial registration-grade detail), but zero efficacy or durability data exist yet — the trial is open-label, uncontrolled, and n≈10, so the current readiness claim rests entirely on dosing having occurred, not on outcomes.
Next
Re-evaluate at the SONIX Phase 1/2 preliminary data readout (targeted YE2026) and again after the 2027 follow-up readouts before any adoption signal.

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
5
Tier 1
0
Tier 2
5
Tier 3
0
Supports
2
Contradicts
1
Context
2
Latest observed
2026-08-13

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-08-17 Reading moved from unknown to unknown.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.